Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2007 June;48(3) > The Journal of Cardiovascular Surgery 2007 June;48(3):323-31

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES  CARDIAC SECTION 

The Journal of Cardiovascular Surgery 2007 June;48(3):323-31

Copyright © 2007 EDIZIONI MINERVA MEDICA

language: English

Evaluation of the topical hemostatic efficacy and safety of TISSEEL VH S/D fibrin sealant compared with currently licensed TISSEEL VH in patients undergoing cardiac surgery: a phase 3, randomized, double-blind clinical study

Lowe J., Luber J., Levitsky S., Hantak E., Montgomery J., Schiestl N., Schofield N., Marra S.

1 Duke University Medical Center Durham, NC, USA 2 Franciscan Health System Research Center Tacoma, WA, USA 3 Department of Surgery Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA 4 Baxter AG Vienna, Austria 5 Baxter Healthcare Corporation Westlake Village, CA, USA 6 UMDNJ Robert Wood Johnson Camden, NJ, USA


PDF


Aim. TISSEEL VH is the only commercially available fibrin sealant indicated as an adjunct to conventional methods of hemostasis during cardiac surgery. A next generation fibrin sealant (TISSEEL VH S/D) has been developed in frozen, ready-to-use form with an added virus inactivation step (solvent/detergent [S/D] treatment) to provide added safety and convenience to the currently licensed product. This study was performed to compare efficacy and safety of the two products.
Methods. Phase 3, prospective, randomized, double-blind, multicenter study to compare TISSEEL VH S/D to TISSEEL VH during cardiac surgery. The primary efficacy endpoint was the proportion of patients who achieved hemostasis at the primary treatment site within 5 min, and maintained hemostasis until surgical closure.
Results. The proportion of patients who achieved hemostasis at the primary treatment site within 5 min, and maintained hemostasis until surgical closure was 88.2% for TISSEEL VH S/D and 89.6% for TISSEEL VH in the intent-to-treat population. The difference in proportions, TISSEEL VH S/D minus TISSEEL VH, was –1.4% with a standard error of 3.70%. The lower 97.5% confidence bound of this difference was –8.6%, which is above the predefined noninferiority margin of 15%. Therefore, TISSEEL VH S/D is at least as efficacious as TISSEEL VH. The safety profile of TISSEEL VH S/D was very similar to that of currently licensed TISSEEL VH as assessed by the safety endpoints.
Conclusion. TISSEEL VH S/D is safe and effective for use as an adjunct to hemostasis in patients undergoing cardiac surgery.

top of page